Abstract 756P
Background
CLDN6 is expressed at high levels in multiple cancers with little to no expression in normal tissues and has been implicated in the initiation, progression, and metastasis of some cancers. CLDN6 is an ideal target for development of new therapeutics. TORL-1-23 is first-in-class ADC targeting the tumor-specific antigen CLDN6.
Methods
This ongoing first in human study (TORL123-001, NCT05103683) characterizes the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of TORL-1-23 in participants with advanced solid tumors. Pharmacokinetics (PK), immunogenicity and clinical efficacy are also assessed. TORL-1-23 is administered IV every 3 weeks. In Dose Escalation, cohorts up to 6 participants are evaluated at each dose level according to an accelerated titration design. In Dose Expansion, patients with CLDN6-expressing cancers will be evaluated to confirm the RP2D in ovarian cancer, NSCLC, and other CLDN6+ cancers using an IHC companion diagnostic. Doses above the historic MTD for MMAE containing ADCs are being evaluated given the favorable safety/tolerability at doses <2.4 mg/kg.
Results
30 patients with ovarian (n=22), testicular (n=5), and endometrial (n=3) cancers were enrolled across 9 dose levels ranging from 0.2 to 3 mg/kg IV every 3 weeks (as of 01MAY2023). 93% of pts had received ≥ 3 prior lines of treatment in the metastatic setting. The most common treatment-related adverse events were Gr1/2 fatigue (n=6), anemia (n=5), and peripheral neuropathy (n=4). No DLTs were observed at doses ≤2.4 mg/kg. Sustained PK exposure of TORL-1-23 over the dosing interval and low levels of circulating MMAE are noted. Partial responses (PR) were observed in 7/22 (32%) efficacy evaluable participants with CLDN6+ disease (6 ovarian, 1 testicular) across dose levels. 3/3 (100%) participants with CLDN6+ ovarian cancer responded at the 2.4 mg/kg dose level. Data from 3 mg/kg are pending.
Conclusions
In participants with heavily-pretreated CLDN6-expressing ovarian cancer, the novel TORL-1-23 ADC has a favorable safety/tolerability profile and encouraging antitumor activity in a phase 1 dose finding study. Further evaluation in ovarian cancer and other CLDN6+ cancers is warranted.
Clinical trial identification
NCT05103683.
Editorial acknowledgement
None.
Legal entity responsible for the study
TORL Biotherapeutics.
Funding
TORL Biotherapeutics.
Disclosure
A. Machado, S. Davenport, S. Bilic, L. Miller, A. Chung: Financial Interests, Institutional, Other, Fee for Service: TORL Biotherapeutics. M.F. Press: Financial Interests, Personal, Advisory Board: Biocartis, Cepheid, Lilly USA, LLC; Financial Interests, Personal, Other, Consultant: Zymeworks, Inc., Eli Lilly & Company, AstraZeneca, Merck, Novartis; Financial Interests, Personal, Ownership Interest: TORL Biotherapeutics LLC; Financial Interests, Institutional, Other, Fee-for-Service Agreements: Zymeworks, Inc., TRIO-US, TRIO; Financial Interests, Institutional, Other, Fee-For-Service Agreements: TORL Biotherapeutics LLC; Financial Interests, Institutional, Other, Fee-for-Service Agreement: Ambrx, 1200 Pharma. S. Letrent: Financial Interests, Personal, Full or part-time Employment: TORL Biotherapeutics. D. Slamon: Financial Interests, Personal and Institutional, Leadership Role: TORL Biotherapeutics; Financial Interests, Personal and Institutional, Ownership Interest: TORL Biotherapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
759P - Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
Presenter: Junjie Wang
Session: Poster session 11
760P - Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
Presenter: Ang Qu
Session: Poster session 11
761P - A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification
Presenter: Josep M. Piulats
Session: Poster session 11
764P - Tislelizumab (Anti-PD-1) combined with definitive chemoradiotherapy in recurrent and/or metastatic cervical cancer (PILOT-2020-511): A single-arm, phase II trial
Presenter: JUN ZHU
Session: Poster session 11
765P - SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Presenter: Xiaohua Wu
Session: Poster session 11
766P - A comparative study of sequential and interdigitated brachytherapy with chemoradiation in patients of locally advanced carcinoma cervix
Presenter: Shreya Singh
Session: Poster session 11
767P - Phase I/II study of toripalimab with cisplatin-based concurrent IMRT for local advanced cervical cancer
Presenter: Ping Jiang
Session: Poster session 11
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11